Lupus Erythematosus, Systemic Clinical Trial
Official title:
Association Between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients With Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the
production of multiple autoantibodies. Antibodies against Ficolin-3 were previously
identified in the sera of some SLE patients, but their prevalence and significance have not
been yet investigated. The aims of this study were to determine the prevalence of
anti-ficolin-3 antibodies among SLE patients and to investigate their potential as
diagnostic and/or prognostic biomarkers in SLE.
In this retrospective study, clinical data were obtained from medical files and blood
samples were selected from preexisting biological collection. SLE patients (n=165) were
informed and did not objected, they were matched to healthy controls (n=48). Disease
activity was determined according to the SLEDAI score. Anti-ficolin-3, anti-dsDNA and
anti-C1q antibodies levels were measured in sera by ELISA. First, a highly significant
difference was found in the anti-ficolin-3 levels between SLE patients and healthy subjects.
Anti-ficolin-3 antibodies were detected as positive in 58 of 165 (35%) SLE patients. The
titer of anti-ficolin-3 antibodies was correlated with the SLEDAI score (p<0.0001). The
presence of anti-ficolin-3 antibodies was associated with anti-C1q and anti-dsDNA
antibodies. Regarding associations with clinical manifestations, only the presence of active
lupus nephritis was significantly associated with the presence of anti-ficolin-3 antibodies
(p=0.0001). This association with renal involvement was higher with anti-ficolin-3
antibodies than with other auto-antibodies. Interestingly, the combination of anti-ficolin-3
and anti-C1q antibodies demonstrated higher specificity than any other traditional
biomarker.
These results suggest that anti-ficolin-3 could be useful for the diagnosis of active
nephritis in SLE patients.
For this retrospective study, a brief summary should be enough. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Recruiting |
NCT05967520 -
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT02875691 -
Effect of Green Tea on Treatment of Lupus
|
Phase 2 | |
| Completed |
NCT02922114 -
Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients
|
N/A | |
| Withdrawn |
NCT01702038 -
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
|
Phase 2 | |
| Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
| Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
| Completed |
NCT00065806 -
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
|
Phase 3 | |
| Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A | |
| Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
| Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
| Recruiting |
NCT05899907 -
Efficacy and Safety of Telitacicept in Early SLE
|
Phase 4 | |
| Completed |
NCT04956484 -
Belimumab In Early Systemic Lupus Erythematosus
|
Phase 4 | |
| Completed |
NCT05326841 -
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
|
Phase 3 | |
| Completed |
NCT02655640 -
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
|
N/A | |
| Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
| Terminated |
NCT00089804 -
Study of LJP 394 in Lupus Patients With History of Renal Disease
|
Phase 3 | |
| Completed |
NCT00071487 -
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
| Completed |
NCT02349061 -
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT05636670 -
Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
|